+-------------------------------------------------+--------------------+
| **[World Trade]{.smallcaps}**                   |                    |
|                                                 |                    |
| **[Organization]{.smallcaps}**                  |                    |
+-------------------------------------------------+--------------------+
|                                                 |                    |
+-------------------------------------------------+--------------------+
|                                                 | **G/TBT            |
|                                                 | /N/USA/214/Add.1** |
|                                                 |                    |
|                                                 | 3 November 2006    |
+-------------------------------------------------+--------------------+
|                                                 | (06-5316)          |
+-------------------------------------------------+--------------------+
|                                                 |                    |
+-------------------------------------------------+--------------------+
| **Committee on Technical Barriers to Trade**    | Original: English  |
+-------------------------------------------------+--------------------+

notification

Addendum

The following communication, dated 31 October 2006, is being circulated
at the request of the Delegation of the United States.

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 20, 201, 207, 314, 330, 514, 515, 601, 607, 610, and

1271

\[Docket No. 2005N-0403\]

RIN 0910-AA49

Requirements for Foreign and Domestic Establishment Registration and
Listing for Human Drugs, Including Drugs That Are Regulated Under a
Biologics License Application, and Animal Drugs; Public Meeting;
Extension of Comment Period

AGENCY: Food and Drug Administration, HHS.

ACTION: Proposed rule; notice of public meeting and extension of comment
period.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

The Food and Drug Administration (FDA) is announcing a public meeting to
discuss the proposed changes to the National Drug Code (NDC) system
contained in the agency\'s proposed rule governing drug establishment
registration and drug listing. The proposed rule appeared in the Federal
Register of August 29, 2006 (71 FR 51276).

In addition, in response to requests for an extension, FDA is extending
to 26 January 2007 the comment period for the proposed rule to provide
interested parties additional time to submit comments.

The public meeting will be held on 11 December 2006 from 9 a.m. to 4
p.m. Register to attend the meeting by November 24, 2006. Submit written
or electronic comments for consideration at the meeting and requests to
speak by 24 November 2006. Submit written or

electronic comments on the proposed rule and this notice by 26 January
2007.

See the full text of G/TBT/N/USA/214/Add.1 online at URLs:

<http://a257.g.akamaitech.net/7/257/2422/01jan20061800/edocket.access.gpo.gov/2006/E6-18310.htm>

<http://a257.g.akamaitech.net/7/257/2422/01jan20061800/edocket.access.gpo.gov/2006/pdf/E6-18310.pdf>

**\_\_\_\_\_\_\_\_\_\_**